The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial.
 
Daniel J. George
Honoraria - Bayer; BIOPHARM; Dendreon; Medivation; Novartis; Sanofi
Consulting or Advisory Role - Acceleron Pharma; Astellas Pharma; Bayer; Bristol-Myers Squibb; Celgene; Dendreon; Exelixis; Genentech; GlaxoSmithKline; Innocrin Pharma; Janssen; Medivation; Merck Sharp & Dohme; Myovant Sciences; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Dendreon; Novartis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Genentech/Roche; Medivation; Merck; Pfizer
 
Colin Hessel
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Susan Halabi
Consulting or Advisory Role - Dendreon; Eisai; Genentech; Sanofi; Tokai Pharmaceuticals
Travel, Accommodations, Expenses - Dendreon
 
Ben L. Sanford
No Relationships to Disclose
 
M. Dror Michaelson
Consulting or Advisory Role - Exelixis; Novartis; Pfizer
Research Funding - Argos Therapeutics; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Merck; Pfizer; Takeda
 
Olwen Mary Hahn
Honoraria - Cardinal Health (I)
Travel, Accommodations, Expenses - Cardinal Health (I)
 
Meghara K. Walsh
No Relationships to Disclose
 
Thomas Olencki
No Relationships to Disclose
 
Joel Picus
Consulting or Advisory Role - Novo Nordisk
Research Funding - Agensys; Altor BioScience; BioClin Therapeutics; Novartis; Oncogenex
 
Eric Jay Small
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics
Honoraria - Janssen-Cilag
Consulting or Advisory Role - Fortis; Gilead Sciences; Valeant Pharmaceuticals International
Research Funding - Janssen (Inst)
 
Shaker R. Dakhil
No Relationships to Disclose
 
Darren R. Feldman
Research Funding - Novartis; Seagen
 
Milan Mangeshkar
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
Travel, Accommodations, Expenses - Exelixis
 
Christian Scheffold
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Michael J. Morris
Consulting or Advisory Role - Astellas Pharma; Bayer; Endocyte
Research Funding - Bayer (Inst); Endocyte (Inst); Progenics (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bayer; Endocyte
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - alligent; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Peloton Therapeutics; Pfizer; Prometheus; Roche/Genentech
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - advisory boards/consultancy